Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection

Koen K.A. Van Rompay, Michael B. McChesney, Nancy L. Aguirre, Kimberli A. Schmidt, Norbert Bischofberger, Marta Marthas

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Simple affordable interventions are needed to reduce vertical human immunodeficiency virus (HIV) transmission in developing countries. The efficacy of 2 low doses (4 mg/kg, subcutaneously) or 1 high dose (30 mg/kg, subcutaneously) of the reverse-transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to protect newborn macaques against simian immunodeficiency virus (SIV) infection was investigated. Thirteen newborn macaques were inoculated orally with virulent SIVmac251. The 4 placebo-treated animals (group A) became persistently infected. Groups B and C (n = 4 in each group) received 2 4-mg/kg doses of PMPA, either 4 h before and 20 h after (group B) or 1 and 25 h after SIV inoculation (group C). One animal (group D) received a single 30-mg/kg dose of PMPA 1 h after SIV inoculation. Despite evidence of an initial transient infection, 3 group B animals, 2 group C animals, and the group D animal were SIV negative and seronegative at ages 19-23 months. Immune activation with recall antigens or pharmacologic immunosuppression with corticosteroids failed to reactivate viral replication. These data suggest that 1 or 2 doses of PMPA may protect human newborns against intrapartum HIV infection.

Original languageEnglish (US)
Pages (from-to)429-438
Number of pages10
JournalJournal of Infectious Diseases
Volume184
Issue number4
DOIs
StatePublished - Aug 15 2001

Fingerprint

Tenofovir
Simian Immunodeficiency Virus
Macaca
Virus Diseases
HIV
Reverse Transcriptase Inhibitors
Adenine
Immunosuppression
Developing Countries
Adrenal Cortex Hormones
Placebos
Antigens

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. / Van Rompay, Koen K.A.; McChesney, Michael B.; Aguirre, Nancy L.; Schmidt, Kimberli A.; Bischofberger, Norbert; Marthas, Marta.

In: Journal of Infectious Diseases, Vol. 184, No. 4, 15.08.2001, p. 429-438.

Research output: Contribution to journalArticle

Van Rompay, Koen K.A. ; McChesney, Michael B. ; Aguirre, Nancy L. ; Schmidt, Kimberli A. ; Bischofberger, Norbert ; Marthas, Marta. / Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. In: Journal of Infectious Diseases. 2001 ; Vol. 184, No. 4. pp. 429-438.
@article{3cdd038ba2944fe181056642fa2c65a9,
title = "Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection",
abstract = "Simple affordable interventions are needed to reduce vertical human immunodeficiency virus (HIV) transmission in developing countries. The efficacy of 2 low doses (4 mg/kg, subcutaneously) or 1 high dose (30 mg/kg, subcutaneously) of the reverse-transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to protect newborn macaques against simian immunodeficiency virus (SIV) infection was investigated. Thirteen newborn macaques were inoculated orally with virulent SIVmac251. The 4 placebo-treated animals (group A) became persistently infected. Groups B and C (n = 4 in each group) received 2 4-mg/kg doses of PMPA, either 4 h before and 20 h after (group B) or 1 and 25 h after SIV inoculation (group C). One animal (group D) received a single 30-mg/kg dose of PMPA 1 h after SIV inoculation. Despite evidence of an initial transient infection, 3 group B animals, 2 group C animals, and the group D animal were SIV negative and seronegative at ages 19-23 months. Immune activation with recall antigens or pharmacologic immunosuppression with corticosteroids failed to reactivate viral replication. These data suggest that 1 or 2 doses of PMPA may protect human newborns against intrapartum HIV infection.",
author = "{Van Rompay}, {Koen K.A.} and McChesney, {Michael B.} and Aguirre, {Nancy L.} and Schmidt, {Kimberli A.} and Norbert Bischofberger and Marta Marthas",
year = "2001",
month = "8",
day = "15",
doi = "10.1086/322781",
language = "English (US)",
volume = "184",
pages = "429--438",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection

AU - Van Rompay, Koen K.A.

AU - McChesney, Michael B.

AU - Aguirre, Nancy L.

AU - Schmidt, Kimberli A.

AU - Bischofberger, Norbert

AU - Marthas, Marta

PY - 2001/8/15

Y1 - 2001/8/15

N2 - Simple affordable interventions are needed to reduce vertical human immunodeficiency virus (HIV) transmission in developing countries. The efficacy of 2 low doses (4 mg/kg, subcutaneously) or 1 high dose (30 mg/kg, subcutaneously) of the reverse-transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to protect newborn macaques against simian immunodeficiency virus (SIV) infection was investigated. Thirteen newborn macaques were inoculated orally with virulent SIVmac251. The 4 placebo-treated animals (group A) became persistently infected. Groups B and C (n = 4 in each group) received 2 4-mg/kg doses of PMPA, either 4 h before and 20 h after (group B) or 1 and 25 h after SIV inoculation (group C). One animal (group D) received a single 30-mg/kg dose of PMPA 1 h after SIV inoculation. Despite evidence of an initial transient infection, 3 group B animals, 2 group C animals, and the group D animal were SIV negative and seronegative at ages 19-23 months. Immune activation with recall antigens or pharmacologic immunosuppression with corticosteroids failed to reactivate viral replication. These data suggest that 1 or 2 doses of PMPA may protect human newborns against intrapartum HIV infection.

AB - Simple affordable interventions are needed to reduce vertical human immunodeficiency virus (HIV) transmission in developing countries. The efficacy of 2 low doses (4 mg/kg, subcutaneously) or 1 high dose (30 mg/kg, subcutaneously) of the reverse-transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to protect newborn macaques against simian immunodeficiency virus (SIV) infection was investigated. Thirteen newborn macaques were inoculated orally with virulent SIVmac251. The 4 placebo-treated animals (group A) became persistently infected. Groups B and C (n = 4 in each group) received 2 4-mg/kg doses of PMPA, either 4 h before and 20 h after (group B) or 1 and 25 h after SIV inoculation (group C). One animal (group D) received a single 30-mg/kg dose of PMPA 1 h after SIV inoculation. Despite evidence of an initial transient infection, 3 group B animals, 2 group C animals, and the group D animal were SIV negative and seronegative at ages 19-23 months. Immune activation with recall antigens or pharmacologic immunosuppression with corticosteroids failed to reactivate viral replication. These data suggest that 1 or 2 doses of PMPA may protect human newborns against intrapartum HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=0035882425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035882425&partnerID=8YFLogxK

U2 - 10.1086/322781

DO - 10.1086/322781

M3 - Article

C2 - 11471100

AN - SCOPUS:0035882425

VL - 184

SP - 429

EP - 438

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -